Pfizer and Ionis announce discontinuation of vupanorsen clinical development program
- Monday, January 31, 2022, 7:11
- PR Newswire
- Add a comment
NEW YORK and CARLSBAD, Calif., Jan. 31, 2022 /PRNewswire/ — Pfizer Inc. (NYSE: PFE) and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the discontinuation of the Pfizer-led clinical development program for vupanorsen (PF-07285557), an investigational antisense therapy that…
About the Author
admin has written 20022 stories on this site.